3.00
-0.03 (-0.99%)
| Previous Close | 3.03 |
| Open | 3.09 |
| Volume | 644,115 |
| Avg. Volume (3M) | 687,361 |
| Market Cap | 224,400,288 |
| Price / Sales | 1.69 |
| Price / Book | 0.600 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -19.77% |
| Operating Margin (TTM) | -61.02% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | -44.70% |
| Total Debt/Equity (MRQ) | 3.58% |
| Current Ratio (MRQ) | 12.34 |
| Operating Cash Flow (TTM) | 27.37 M |
| Levered Free Cash Flow (TTM) | 12.04 M |
| Return on Assets (TTM) | -4.80% |
| Return on Equity (TTM) | -7.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | OraSure Technologies, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 4.83% |
| % Held by Institutions | 89.49% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Aug 2025 | Announcement | OraSure Announces Second Quarter 2025 Financial Results |
| 04 Aug 2025 | Announcement | OraSure Appoints Anne Messing as Chief Commercial Officer |
| 21 Jul 2025 | Announcement | OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th |
| 10 Jul 2025 | Announcement | OraSure Launches Novel Blood Collection Device for Proteomic Research |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |